Twist Bioscience Corporation cash flow to debt ratio of -34.68% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Twist Bioscience Corporation's free cash flow has decreased 9.34% from $-69.17M last year to $-75.63M, signaling decreasing performance

Twist Bioscience Corporation's debt to equity ratio is 0.21, which means that the company's assets are healthy financed, signaling financial stability. READ MORE: A ratio under 0.60 means the company finances its assets with own equity, signaling financial stability and good management.

Twist Bioscience Corporation's debt has increased relative to shareholder equity from 0.18 last year to 0.21 today, signaling weakened financials

Twist Bioscience Corporation has negative EBITDA, making leverage ratio unreliable

Twist Bioscience Corporation earns at least as much interest as it pays. Interest obligations are fully covered.

Twist Bioscience Corporation's profit margin has increased (-70.24%) in the last year from -66.69% to -19.85%, signaling increasing performance

Twist Bioscience Corporation's short-term assets of $332.97M exceed its short-term liabilities of $91.41M

Twist Bioscience Corporation's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Twist Bioscience Corporation's return on equity of -17.46%, is lower than 15.00%, indicating bad performance

Twist Bioscience Corporation's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Twist Bioscience Corporation had positive net income in only 0.00 out of 5 years, indicating unstable earnings

Twist Bioscience Corporation has negative free cash flow, indicating the company is burning cash rather than generating it

Twist Bioscience Corporation has negative free cash flow, indicating cash burn

Twist Bioscience Corporation's yearly earnings has increased -62.79% since last year from $-208.73M to $-77.67M, signaling increasing performance

Twist Bioscience Corporation's yearly revenue has increased 20.32% since last year from $312.97M to $376.57M, signaling increasing performance

ROIC -24.50% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Twist Bioscience Corporation's 3-year revenue CAGR of 22.76% is positive, indicating growing revenue over the past 3 years

Twist Bioscience Corporation had revenue growth in 5.00 out of 5 years, indicating consistent revenue performance

Twist Bioscience Corporation had positive ROE in only 0.00 out of 5 years, indicating inconsistent returns on equity

Twist Bioscience Corporation has insufficient data to evaluate this check.

Twist Bioscience Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Twist Bioscience Corporation is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Twist Bioscience Corporation has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Twist Bioscience Corporation is overvalued relative to its fair value price of -107.97 based on Earnings Fair Value model

Twist Bioscience Corporation has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Twist Bioscience Corporation has a price-to-book ratio of 12.55x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

Twist Bioscience Corporation has a price-to-sales ratio of 13.94x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue